In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
If the claim is....then why ?
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.010(3.77%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $162.7K | 620.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25008 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 34768 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |